Compound class:
Antibody
Comment: Zadoprubart is the INN for an anti-B and T lymphocyte attenuator (BTLA) monoclonal antibody. We have been unable to associate this with a clinical candidate or company research code.
There is information confirming two anti-BTLA monoclonals that were progressed to clinical development: HFB200603 (HiFiBiO; Phase 1 NCT05789069, solid tumours) [2] and ANB032 (AnaptysBio; Phase 2 NCT05935085, atopic dermatitis; terminated due to insufficient efficacy) [1]. |